Lineage Cell Therapeutics Inc Cash Flow Conversion Efficiency
Lineage Cell Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) has a cash flow conversion efficiency ratio of -0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.62 Million) by net assets ($20.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lineage Cell Therapeutics Inc (1991–2024)
Cash flow conversion efficiency of Lineage Cell Therapeutics Inc from 1991 to 2024. This chart illustrates how Lineage Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Lineage Cell Therapeutics Inc for real-time trading data and today's change.
Lineage Cell Therapeutics Inc Cash Flow Conversion Ratio Explained
Lineage Cell Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lineage Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lineage Cell Therapeutics Inc ranked by their cash flow conversion efficiency. Also see LCTX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Websol Energy System Limited
NSE:WEBELSOLAR
|
0.338x |
|
Shenzhen Kexin Communication Technologies Co Ltd
SHE:300565
|
-0.061x |
|
Transcontinental Inc
TO:TCL-A
|
-0.095x |
|
Colonial Coal International Corp
V:CAD
|
-0.023x |
|
Dalian Friendship Group Co Ltd
SHE:000679
|
-0.543x |
|
Shanghai Kaichuang Marine International Co Ltd
SHG:600097
|
0.041x |
|
Ernst Russ AG
XETRA:ERAG
|
0.067x |
|
Hyliion Holdings Corp.
NYSE:HYLN
|
-0.052x |
Annual Cash Flow Conversion Efficiency for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual cash flow conversion efficiency of Lineage Cell Therapeutics Inc from 1991 to 2024. Review how much free cash does Lineage Cell Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $77.01 Million | $-23.09 Million | -0.300x | +34.90% |
| 2023-12-31 | $62.02 Million | $-28.57 Million | -0.461x | -3228.58% |
| 2022-12-31 | $71.94 Million | $1.06 Million | 0.015x | +105.68% |
| 2021-12-31 | $90.90 Million | $-23.56 Million | -0.259x | -24.83% |
| 2020-12-31 | $95.13 Million | $-19.75 Million | -0.208x | +27.69% |
| 2019-12-31 | $111.25 Million | $-31.95 Million | -0.287x | +14.22% |
| 2018-12-31 | $92.25 Million | $-30.88 Million | -0.335x | -80.20% |
| 2017-12-31 | $164.26 Million | $-30.52 Million | -0.186x | +42.72% |
| 2016-12-31 | $130.51 Million | $-42.33 Million | -0.324x | +44.34% |
| 2015-12-31 | $76.45 Million | $-44.54 Million | -0.583x | +5.94% |
| 2014-12-31 | $62.72 Million | $-38.85 Million | -0.619x | +11.28% |
| 2013-12-31 | $42.26 Million | $-29.51 Million | -0.698x | +13.80% |
| 2012-12-31 | $24.29 Million | $-19.68 Million | -0.810x | -147.04% |
| 2011-12-31 | $41.46 Million | $-13.59 Million | -0.328x | -109.58% |
| 2010-12-31 | $49.43 Million | $-7.73 Million | -0.156x | +59.43% |
| 2009-12-31 | $11.05 Million | $-4.26 Million | -0.386x | -204.49% |
| 2008-12-31 | $-4.35 Million | $-1.60 Million | 0.369x | -9.33% |
| 2007-12-31 | $-3.05 Million | $-1.24 Million | 0.407x | -39.85% |
| 2006-12-31 | $-1.87 Million | $-1.26 Million | 0.677x | -90.59% |
| 2005-12-31 | $-196.58K | $-1.41 Million | 7.194x | +261.40% |
| 2004-12-31 | $344.77K | $-1.54 Million | -4.457x | -1756.11% |
| 2003-12-31 | $-2.43 Million | $-654.14K | 0.269x | -85.20% |
| 2002-12-31 | $-1.17 Million | $-2.13 Million | 1.818x | -94.39% |
| 2001-12-31 | $-99.09K | $-3.21 Million | 32.392x | +978.80% |
| 2000-12-31 | $1.32 Million | $-4.86 Million | -3.686x | -326.31% |
| 1999-12-31 | $5.08 Million | $-4.39 Million | -0.865x | +1.19% |
| 1998-12-31 | $2.40 Million | $-2.10 Million | -0.875x | -337.50% |
| 1997-12-31 | $6.50 Million | $-1.30 Million | -0.200x | +73.33% |
| 1996-12-31 | $2.80 Million | $-2.10 Million | -0.750x | 0.00% |
| 1995-12-31 | $2.80 Million | $-2.10 Million | -0.750x | -20.00% |
| 1994-12-31 | $3.20 Million | $-2.00 Million | -0.625x | -126.56% |
| 1993-12-31 | $5.80 Million | $-1.60 Million | -0.276x | +27.85% |
| 1992-12-31 | $3.40 Million | $-1.30 Million | -0.382x | -193.14% |
| 1991-12-31 | $4.60 Million | $-600.00K | -0.130x | -- |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more